Heparin Panpharma (Heparin Sodium)

Heparin Panpharma is indicated for several clinical situations where inhibition of clot formation is required.

• Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism.
• Prophylaxis of clot formation during cardiac surgery, coronary artery bypass grafting, and other cardiovascular procedures.
• Anticoagulation support during hemodialysis or extracorporeal circulation to prevent circuit clotting.
• Management of acute coronary syndromes, such as unstable angina or non‑ST‑segment elevation myocardial infarction.
• Use in obstetric settings for prevention of thrombosis in high‑risk pregnant patients, when clinically indicated.

Adverse reactions to Heparin Panpharma vary in frequency and severity; they are categorized as common or serious.

Common

• Minor bleeding at injection site or bruising.
• Small drops in platelet count without clinical symptoms.
• Transient elevation of liver enzymes.
• Mild allergic skin reactions such as rash or pruritus.
• Elevated activated partial thromboplastin time (aPTT) indicating prolonged clotting time.

Serious

• Major hemorrhage, including internal or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Severe hypersensitivity reactions, including anaphylaxis.
• Spontaneous spinal or epidural hematoma, especially after neuraxial procedures.
• Life‑threatening bleeding requiring transfusion or surgical intervention.

When prescribing Heparin Panpharma, clinicians should evaluate patient‑specific factors and monitor laboratory parameters to reduce risk.

• Assess for active bleeding, recent surgery, or trauma before initiating therapy.
• Use caution in patients with a history of heparin‑induced thrombocytopenia or known hypersensitivity.
• Adjust dose in renal or hepatic impairment, as drug clearance may be altered.
• Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels to maintain therapeutic range.
• Evaluate platelet counts regularly to detect early signs of HIT.
• Consider pregnancy status; benefits must outweigh potential fetal risks.

Heparin Panpharma can interact with other agents that affect hemostasis or drug metabolism; awareness of these interactions guides safe co‑administration.

Avoid

• Concurrent use with other anticoagulants such as warfarin, direct oral anticoagulants, or high‑dose aspirin, which may increase bleeding risk.
• Administration with thrombolytic agents (e.g., alteplase, streptokinase) that potentiate fibrinolysis.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that impair platelet function.

Use with caution

• Concomitant use of antiplatelet drugs (clopidogrel, ticagrelor) requires close monitoring of bleeding.
• Concurrent therapy with drugs that reduce platelet count (e.g., quinine, carboplatin) may heighten HIT risk.
• Use with medications that affect renal function (e.g., aminoglycosides) may necessitate dose adjustment.